Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Samuel Ganz (NPI 1447591714)

Field	Value
Entity Type	Individual
Organization	Samuel Ganz
Address	4800 Linton Blvd Ste F107
City	Delray Beach
State	FL
ZIP	33445
Taxonomy	Internal Medicine Physician
NPI Enumerated	March 11, 2013

Payer Source	Total Paid
Medicare	$5.3M
Medicaid	$0

Key Findings

Provider profile and payor scale: SAMUEL GANZ, an Internal Medicine physician in DELRAY BEACH, FL, has been NPI-enumerated since 2013-03-11 (~13 years ago) and reports $5.3M in lifetime Medicare revenue with none for Medicaid (no Medicaid billing on file). This makes the practice effectively single-payer (Medicare-focused) in the available claims data, concentrating commercial risk and revenue exposure in the Medicare program.

Revenue concentration in Medicare: this provider’s top three Medicare codes—J3241 ($2.1M, 39.5% of Medicare revenue), J1306 ($907.4K, 17.3%), and J0897 ($656.6K, 12.6%)—together account for 69.4% of total Medicare revenue. That level of concentration indicates the practice derives the bulk of its Medicare receipts from a small set of high-value injectable biologic/drug administration codes.

Service-line implications: the dominant codes (J3241, J1306, J0897) and additional administration codes (96401 $60.8K; 96413 $37.8K; 96365 $14.9K) indicate an operation oriented to in-office parenteral therapy and specialty injectable drug delivery rather than purely eval-and-management clinic visits. The presence of multiple chemotherapy/infusion administration codes alongside high-revenue injectable drug codes suggests infrastructure for frequent on-site injections or infusions and nursing/infusion workflows.

Competitive standing on inclisiran (J1306): the provider is a national outlier for J1306, with $907.4K revenue, ranking #2 of 462 providers nationally and described as an "extreme outlier, far above typical national volume for this code." This rank implies the practice is a major national administrator of this specific drug relative to peers and likely a referral destination for patients needing that therapy.

Competitive standing on denosumab (J0897) and teprotumumab (J3241): for J0897 the provider reports $656.6K and ranks #59 of 10057 (99th percentile; "extreme outlier, far above typical national volume"), indicating a very strong national position for denosumab administration. By contrast, J3241 accounts for $2.1M but ranks #4 of 6 (40th percentile; "typical, unremarkable volume"), so despite high absolute revenue from J3241 this provider is not a high-volume national leader for that particular code relative to a very small national cohort.

Other statistical signals: the practice shows unusually high relative activity for chemotherapy administration code 96401 ($60.8K, rank #65 of 3868; 98th percentile; "extreme outlier") and above-typical volume for romosozumab J3111 ($579.6K, rank #32 of 970; 97th percentile; "notably above typical national volume"). These elevated percentiles across multiple administration codes reinforce that this provider operates at significantly higher-than-typical volumes for in-office drug administration compared with national peers.

Payor mix and contracting implications: with $5.3M in Medicare revenue and no Medicaid on file, the provider is effectively Medicare-dependent in the available claims record; that concentration suggests negotiations, reimbursement risk, and growth strategies should be evaluated primarily in the context of Medicare rates and specialty drug reimbursement policies. The absence of Medicaid activity also implies limited exposure to state Medicaid formularies and rates, which could affect pricing leverage and patient population mix.

Operational and referral implications: the combination of extreme national standing on select biologic injections (J1306, J0897) and high-volume administration codes suggests the practice may function as a regional or national referral center for specialty injectable therapies, with established supply-chain and infusion capabilities. However, variability in rank across drugs (extreme outlier for some, typical for others) indicates the practice’s dominance is drug-specific rather than uniformly across all specialty injectables.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3241	Injection, teprotumumab-trbw, 10 mg	8,290	$250	$2.1M
J1306	Injection, inclisiran, 1 mg	100,820	$10	$907.4K
J0897	Injection, denosumab, 1 mg	36,480	$20	$656.6K
J3245	Injection, tildrakizumab, 1 mg	5,900	$110	$649K
J3111	Injection, romosozumab-aqqg, 1 mg	72,450	$10	$579.6K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	2,930	$30	$99.5K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,430	$30	$89.2K
J0174	Lecanemab-irmb, for intravenous injection, 1 mg	61,000	$1	$61K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	1,030	$60	$60.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	360	$110	$37.8K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Samuel Ganz — 5 of 18 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3241	1	10	6,350	$250	$1.6M
J3245	4	20	4,000	$110	$498.6K
J0129	116	130	9,350	$30	$386.8K
J3111	3	140	16,170	$10	$166.4K
J1306	1	50	8,800	$10	$115.1K
J0897	6	1,060	3,290	$20	$106.5K
J1745	36	120	2,060	$30	$80.9K
J0174	4	10	61,060	$1	$68.2K
96413	201	730	200	$100	$26.1K
Q0138	169	270	33,410	$1	$16.9K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with Samuel Ganz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wayne Memorial Community Health Centers	PA	Federally Qualified Health Center (FQHC)	$0	$17.1M
Wayne Memorial Community Health Centers	PA	Federally Qualified Health Center (FQHC)	$0	$10.5M
Abdalla Sholi	PA	Hematology & Oncology Physician	$134.2K	$3.2K
Sean Mcveigh	PA	Pulmonary Disease Physician	$108.8K	$0
Ramesh Pandit	DE	Internal Medicine Physician	$83.1K	$0
Mehran Hamzeh Langroudi	DE	Obstetrics & Gynecology Physician	$7K	$64.4K

Nearby Providers

Other providers in the same ZIP code as Samuel Ganz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ambassador Health Services Inc	FL	Home Health Agency	$0	$14.7M
Etan Marks	FL	Dermatopathology (Pathology) Physician	$2.7M	$0
Genetics Institute Of America Laboratory Fl1 Corp	FL	Clinical Medical Laboratory	$2.3M	$0
The Outpatient Center, LLC	FL	Ambulatory Surgical Clinic/Center	$1.8M	$0
Delray Beach Asc, LLC	FL	Ambulatory Surgical Clinic/Center	$1.6M	$0
Kimberly Balshi	FL	Nurse Practitioner	$1.3M	$0
Jason Rosen	FL	Dermatopathology Physician	$1.1M	$0
Aaron Weiss	FL	Gastroenterology Physician	$948.1K	$0
Morris Naus	FL	Gastroenterology Physician	$866.2K	$0
Lianne Cavell	FL	Gastroenterology Physician	$514.8K	$0

Samuel Ganz — Billing Profile & Reimbursement Data

Sign up for Samuel Ganz — Billing Profile & Reimbursement Data policy alerts

Samuel Ganz — Billing Profile & Reimbursement Data

Sign up for Samuel Ganz — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References